Donepezil Market Report 2026

Donepezil Market Overview

• Donepezil market size has reached to $1.04 billion in 2025 • Expected to grow to $1.3 billion in 2030 at a compound annual growth rate (CAGR) of 4.5% • Growth Driver: Rising Alzheimer’s Cases Propel Growth Of The Market • Market Trend: Pharma Companies Advance Transdermal Delivery Systems To Boost Compliance In Alzheimer’s Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Donepezil Market?

Donepezil refers to a medication used to treat symptoms of Alzheimer's disease by inhibiting the breakdown of acetylcholine, a neurotransmitter important for memory and cognition. It works as a cholinesterase inhibitor, improving cognitive function and slowing the progression of symptoms in patients with mild to moderate Alzheimer's disease. The main types of donepezil are 5 mg, 10 mg, and 23 mg. Donepezil 5 mg refers to a specific dosage of the medication donepezil hydrochloride, which is primarily used to treat dementia associated with Alzheimer's disease. They treated various routes of administration, such as oral and transdermal, and used different applications like hospitals, clinics, and drugstores.

What Is The Donepezil Market Growth Forecast?

The donepezil market size is expected to see steady growth in the next few years. It will grow to $1.3 billion in 2030 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to growth in elderly population worldwide, increasing awareness of early dementia treatment, rising demand for cost-effective generics, expansion of home-based cognitive care, increasing healthcare expenditure on neurodegenerative diseases. Major trends in the forecast period include rising long-term use in alzheimer’s disease management, increasing preference for oral cognitive enhancement therapies, growing demand for generic donepezil formulations, expansion of treatment in mild to moderate alzheimer’s cases, increased focus on geriatric neurology care.

Global Donepezil Market Segmentation

1) By Type: 5mg, 10mg, 23mg 2) By Route Of Administration: Oral, Transdermal 3) By Application: Hospitals, Clinics, Drugstore

What Is The Driver Of The Donepezil Market?

The increasing prevalence of alzheimer's disease is expected to propel the growth of the donepezil market going forward. Alzheimer's disease is a progressive neurological disorder that causes the degeneration and death of brain cells, leading to memory loss, cognitive decline, and behavioral changes. The Alzheimer's disease cases are increasing due to several reasons, such as an aging population, population growth, lifestyle-related factors, an increase in chronic diseases, genetic factors, and environmental exposures. Donepezil serves as an effective symptomatic treatment for Alzheimer's disease by enhancing cognitive function and daily living skills through its action on acetylcholine levels in the brain. For instance, in May 2024, according to a report by the Alzheimer’s Association, a US-based nonprofit organization dedicated to Alzheimer's care, support, and research, the number of Americans aged 65 and older diagnosed with Alzheimer's dementia rose from 6.5 million in 2022 to an estimated 6.9 million in 2024. Therefore, the rising incidence of alzheimer’s is driving the growth of the donepezil industry.

Key Players In The Global Donepezil Market

Major companies operating in the donepezil market are AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Inc., Intas Pharmaceuticals Ltd., Mylan NV, Sandoz Group AG, Hetero Drugs Ltd., Sun Pharmaceutical Inc., Eisai Co. Ltd., Cipla Ltd., Dr Reddy's Laboratories, Apotex Inc., H Lundbeck A/S, Zydus Cadila, Amneal Pharmaceuticals LLC, Torrent Pharmaceuticals Ltd, Alkem Laboratories Ltd., Jubilant Pharmova Ltd., Wockhardt Ltd., Luoxin Pharmaceuticals Group

Global Donepezil Market Trends and Insights

Major companies operating in the donepezil market are focusing on developing advanced delivery technologies, such as once-weekly and extended-release transdermal systems, to improve compliance and reduce treatment-related discomfort in Alzheimer’s patients. A donepezil transdermal system delivers the drug through the skin at a controlled rate, avoiding first-pass metabolism and lowering the risk of gastrointestinal side effects that often accompany oral dosing. For instance, in March 2024, Corium, Inc., a US-based biopharmaceutical company, introduced its next-generation Adlarity formulation with enhanced patch adhesion, improved skin tolerability, and a more stable 7-day release profile that supports uninterrupted therapeutic exposure. Corium designed this upgraded system to streamline Alzheimer’s care by reducing dosing burden and improving adherence in older adults who struggle with daily oral medication regimens.

What Are Latest Mergers And Acquisitions In The Donepezil Market?

In August 2023, Corium Innovation Inc., a US-based biopharmaceutical company, partnered with Lotus Pharmaceuticals. The partnership aims to create innovations such as Innovative Alzheimer’s Disease Treatment ADLARITY in Multiple Markets Across Asia and License Agreement for ADLARITY (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia. Lotus Pharmaceutical is a Taiwan-based pharmaceutical company focused on commercializing novel and generic pharmaceuticals.

Regional Insights

North America was the largest region in the donepezil market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Donepezil Market?

The donepezil market consists of sales of orally disintegrating tablets, experimental and niche products, active pharmaceutical ingredients, and combination medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Donepezil Market Report 2026?

The donepezil market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the donepezil industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.